Skip to content

Helping Tuberculosis patients accept their condition and follow treatment.

Efficacy of Acceptance and Commitment Therapy on Illness Acceptance and Medication Adherence Among Patients With Multi-Drug Resistant Tuberculosis - ACT-MDR-TB

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080475
Enrollment
60
Registered
2025-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A00-B99- Certain infectious and parasitic diseases

Interventions

Intervention1: Acceptance and Commitment Therapy (ACT): ACT is a form of psychotherapy that uses mindfulness and behavioral strategies to increase psychological flexibility. It will be delivered over

Sponsors

Swatantra Kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The study will include multi-drug resistant tuberculosis (MDR-TB) patients aged 18 to 45 years who provide written informed consent for participation in either the Acceptance and Commitment Therapy (ACT) group or the Treatment as Usual (TAU) group. Eligible participants must have a confirmed diagnosis of MDR-TB through sputum microscopy and culture and should be within 6 to 9 months of diagnosis, actively undergoing standard anti-tuberculosis treatment (such as DOTS or an alternative regimen) in an outpatient setting. Additionally, participants must have basic Hindi or English reading and writing skills to comprehend the intervention materials effectively.

Exclusion criteria

Exclusion criteria: The study will exclude MDR-TB patients who do not provide written informed consent for either the ACT or TAU group. Patients with cognitive impairments, a history or current diagnosis of psychiatric or major medical illnesses, or those undergoing psychiatric or psychological interventions during the study will not be included. Additionally, individuals with drug or substance dependence that may hinder participation in the intervention process will be excluded.

Design outcomes

Primary

MeasureTime frame
Illness Acceptance (measured using Acceptance of illness scale at Baseline (Week 0), Post-Intervention (Week 8)Timepoint: Illness Acceptance (measured using Acceptance of illness scale at Baseline (Week 0), Post-Intervention (Week 8)

Secondary

MeasureTime frame
Illness Acceptance (measured using Acceptance of illness scale at Baseline (Week 0), Post-Intervention (Week 8)Timepoint: Illness Acceptance (measured using Acceptance of illness scale at Baseline (Week 0), Post-Intervention (Week 8)

Countries

India

Contacts

Public ContactDr. Syed Sajid Husain Kazmi

Amity University Uttar pradesh

sshkazmi@lko.amity.edu8565001786

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026